Skip to content
RDL
Network
Ekosistem
Uygulama değiştir
EN
Hakkımızda
SSS
Giriş yap
Başla
Design and synthesis of a new series of modified CH-diarylpyrimidines as drug-resistant HIV non-nucleoside reverse transcriptase inhibitors — Ge Meng (2014) | RDL Network
Back
Cite
Save
Save for later
Share
Home
Publications
Design and synthesis of a new series of modified CH-diarylpyrimidines as drug-resistant HIV non-nucleoside reverse transcriptase inhibitors
Shared by
De Clercq Erik
KU Leuven
Design and synthesis of a new series of modified CH-diarylpyrimidines as drug-resistant HIV non-nucleoside reverse transcriptase inhibitors
Article
2014
en
Authors
+5 more
GM
Ge Meng
YL
Yang Liu
AZ
Aqun Zheng
Discussion
(0)
Sign in
to like and join the discussion.
No comments yet. Be the first to comment.
Related publications
Article
2014
Design and synthesis of a new series of cyclopropylamino-linking diarylpyrimidines as HIV non-nucleoside reverse transcriptase inhibitors
Yang Liu
,
Ge Meng
,
Aqun Zheng
,
Fen‐Er Chen
,
Wenxue Chen
,
De Clercq Erik
,
Christophe Pannecouque
,
Jan Balzarini
Article
2009
Design, Synthesis, and SAR of Naphthyl‐Substituted Diarylpyrimidines as Non‐Nucleoside Inhibitors of HIV‐1 Reverse Transcriptase
Yonghong Liang
,
Xiaoqing Feng
,
Zhao‐Sen Zeng
,
Fen‐Er Chen
,
Jan Balzarini
,
Christophe Pannecouque
,
De Clercq Erik
Article
2010
Lead Optimization of Diarylpyrimidines as Non‐nucleoside Inhibitors of HIV‐1 Reverse Transcriptase
Zhao‐Sen Zeng
,
Yonghong Liang
,
Xiaoqing Feng
,
Fen‐Er Chen
,
Christophe Pannecouque
,
Jan Balzarini
,
De Clercq Erik
Article
2014
Structural modifications of CH(OH)-DAPYs as new HIV-1 non-nucleoside reverse transcriptase inhibitors
Zihong Yan
,
Xiayun Huang
,
Hai-Qiu Wu
,
Wenxue Chen
,
Qiuqin He
,
Fen‐Er Chen
,
De Clercq Erik
,
Christophe Pannecouque
Article
2017
Discovery of Biphenyl-Substituted Diarylpyrimidines as New Non-Nucleoside HIV-1 Reverse Transcripttase Inhibitors
Kaijun Jin
,
Ge Meng
,
Fen‐Er Chen
,
De Clercq Erik
,
Christophe Pannecouque
Discussion(0)
No comments yet. Be the first to comment.